Editing Castrate-Resistant Prostate Cancer (section)

===== mCRPC who progress after docetaxel-based chemotherapy =====
* '''Options with survival benefit (5):'''
** '''Cabazitaxel''' (25 mg/m2) plus prednisone (5 mg/day) '''TROPIC trial'''
** '''Radium-223 every four weeks for six cycles ALSYMPCA trial'''
** '''If not received prior to docetaxel:'''
*** '''Abiraterone acetate''' (1000 mg per day) '''plus prednisone''' (5 mg twice daily) '''COU-AA-301 trial'''
*** '''Enzalutamide''' (160 mg/day) '''AFFIRM trial'''
* '''Options with unknown survival benefit'''
** '''Docetaxel plus prednisone re-exposure in patients who have had a previous favourable response to docetaxel may be reasonable'''
** '''Mitoxantrone may be considered a therapeutic option in symptomatic patients with mCRPC in the first- or second-line setting. Mitoxantrone has not shown any survival advantage but may provide symptomatic relief'''